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Introduction {#sec006}
============

The concept of fragility was introduced by Feinstein (1990) in the epidemiology literature \[[@pone.0237879.ref001]\] but has enjoyed a resurgence in the assessment of biomedical research due to its straightforward and intuitive interpretation \[[@pone.0237879.ref002], [@pone.0237879.ref003]\]. The fragility index (FI) represents the minimum number of events required to change the statistical significance of a study result from significant to nonsignificant \[[@pone.0237879.ref002]\], and has largely been promoted as a measure to assess the robustness of randomised controlled trial (RCT) results with a dichotomous endpoint. Evaluations of FI have been performed in diverse areas ranging from heart failure \[[@pone.0237879.ref004]\], diabetes \[[@pone.0237879.ref005]\], nephrology \[[@pone.0237879.ref006]\], anaesthesiology \[[@pone.0237879.ref007]\], oncology \[[@pone.0237879.ref008]\], ischaemic stroke \[[@pone.0237879.ref009]\], intracranial haemorrhage \[[@pone.0237879.ref010]\], to paediatrics \[[@pone.0237879.ref011]\]. These studies have demonstrated that many RCTs have a low FI, with median FI ranging from 2 to 26 (median of the median 4), suggesting that the interpretation of RCT results commonly hinge on a small number of results.

While being promoted as an easy to understand measure, the properties of FI have not been well elucidated. Carter et al. \[[@pone.0237879.ref012]\] performed simulations of clinical trials and demonstrated that FI is inversely correlated with *P* value and increases with sample size, despite a constant underlying true response rate. Thus, they concluded that FI is a reflection of *P* value and therefore is not an indicator of treatment effect size. A fragility quotient (FQ) has been proposed \[[@pone.0237879.ref013]\], defined as the FI divided by the total sample size. Although simple, it is not clear that a linear scaling of FI enables direct comparison across studies of different sample size \[[@pone.0237879.ref014]\]. The use of FI as a measure of robustness is not without limitations either. These include its applicability only to balanced RCTs with two groups and dichotomous outcomes \[[@pone.0237879.ref002]\]. Furthermore, FI alone does not convey a measure of precision. Therefore, some have argued that FI needs to be interpreted in conjunction with other measures including *P* value, sample size, confidence interval and number lost to follow-up \[[@pone.0237879.ref012]--[@pone.0237879.ref015]\].

The purpose of this work is to demonstrate the application of FI analysis to the traumatic brain injury (TBI) literature and also to assess the utility of FI as a measure of robustness. Despite considerable effort being dedicated to randomised controlled trials in the study of TBI, the results have proven difficult to translate to clinical practice \[[@pone.0237879.ref016]\]. The guidelines for the management of severe TBI as published by the Brain Trauma Foundation are now in their 4^th^ edition \[[@pone.0237879.ref017]\], and encompass a wide-range of management criteria including decompressive craniectomy, steroids and nutrition, hyperosmolar therapy, seizure prophylaxis, and sedation strategies. The guidelines are a careful synthesis of the available published evidence and comprise of five Class 1, 46 Class 2, 136 Class 3 studies, and two meta-analyses. Study designs include a mix of randomised controlled trials (RCTs) as well as observational studies. The guidelines were therefore used to identify RCTs for fragility analysis. The properties of FI were subsequently explored using numerical simulations.

Methods {#sec007}
=======

Two reviewers (TMC and RWS) independently reviewed abstracts or full-text articles of all identified RCTs from Part 1 (treatments) of the guidelines for the management of severe TBI as published by the Brain Trauma Foundation (4^th^ edition) \[[@pone.0237879.ref017]\]. In order to qualify for inclusion, an RCT had to be of parallel 2-group design (i.e. intervention and control/comparator) with patient randomisation in a balanced 1:1 manner and report at least one dichotomous outcome regardless of statistical significance. In studies reporting multiple suitable outcomes, only one outcome was analysed for fragility, preferably the primary outcome. Before proceeding to data extraction, a consensus was reached on the RCTs meeting the inclusion criteria. Any disagreement was resolved by a third reviewer (M-ST).

Data extraction was performed independently by two reviewers (TMC and RWS). Data extracted included the trial outcome, the number of patients randomised to intervention and control/comparator group, the number who experienced an outcome in the intervention and the control/comparator group, and the number lost to follow-up. Studies were also assessed to determine if power analysis and sample size calculations were performed.

All analyses and simulations were performed using MATLAB 2019b (The MathWorks, Inc.). A custom routine was used to calculate the FI \[[@pone.0237879.ref002]\]. A two-by-two contingency table of treatment group against outcome (event or non-event) was constructed for each individual study. If the initial Fisher's exact test yielded a "significant" *P* value (i.e. *P* \< 0.05), an event was added to the group with fewer events (and a non-event was subtracted from the same group) and Fisher's exact test was re-calculated. This was iteratively performed until the *P* value of Fisher's exact test was greater or equal to 0.05. The FI~F~ was then taken to be the number of events added to achieve a "non-significant" *P* value. Alternatively, if the initial Fisher's exact test produced a "non-significant" *P* value (i.e. *P* ≥ 0.05), an event was subtracted from the group with fewer events (and a non-event was added to the same group) iteratively until a significant test result was reached. Since relative risk is commonly used to measure effect size in RCTs \[[@pone.0237879.ref018]\], a similar analysis was performed based on one-sided significance testing of relative risk with a significance level of 0.05, yielding FI~RR~.

Power and sample size analysis {#sec008}
------------------------------

Hypothetical studies were simulated using a combination of study power (1---β) ranging from 0.5 to 0.9, baseline risk in the comparator (control) group ranging from 0.05 to 0.4, and relative risk (*R*) ranging from 0.5 to 2.0 (excluding 1.0). There were 152 combinations for each power level, giving a total of 760 combinations investigated. Using these parameters, sample size calculations were performed as described previously \[[@pone.0237879.ref019]\]. In brief, suppose the true population proportions are *P*~1~ and *P*~2~. The null and alternative hypotheses being tested are $$H_{0}:\mspace{360mu} P_{1} = P_{2}$$ $$H_{1}:\mspace{360mu}\frac{P_{1}}{P_{2}} = R\mspace{360mu}\left( \text{for}\mspace{360mu}{R \neq 1} \right)$$

The baseline risk (in group 2) is assumed to be known and equal to *P*. The combined sample proportion, *p*~c~, is not known but can be approximated by $$p_{c} \approx \mspace{360mu}\frac{P\left( R + 1 \right)}{2}$$

Then, for a one-sided test, the total sample size *N* for a balanced study is given by $$N = \frac{2}{\left( {R - 1} \right)^{2}P^{2}}\left\lbrack {z_{\propto}\sqrt{2p_{c}\left( 1 - p_{c} \right)} + z_{\beta}\sqrt{RP\left( {1 - RP} \right) + P\left( 1 - P \right)}} \right\rbrack^{2}$$ where *z*~α~, *z*~β~ are critical values of the normal distribution. For a study described by a certain set of parameters, the size of each study group and the expected event counts in each group were obtained under the assumption the alternative hypothesis *H*~1~ was true, using the calculated total sample size *N*. The significance level (α) was set to 0.05 in all simulations.

Results {#sec009}
=======

Characteristics of included trials and outcomes {#sec010}
-----------------------------------------------

The review of the TBI guidelines yielded 43 studies that met the inclusion criteria. The studies and the outcomes investigated are listed in S1 Table in [S1 File](#pone.0237879.s001){ref-type="supplementary-material"}. One included study (Study ID 4 in S1 Table in [S1 File](#pone.0237879.s001){ref-type="supplementary-material"}) was underway but not yet completed at the time of publication of the guidelines. These studies were enlisted from eight of the 11 topics in the recommendations for treatment interventions in managing severe TBI. No studies from the topics of cerebrospinal fluid drainage, ventilation therapies or deep vein thrombosis prophylaxis met the inclusion criteria. In most topics, a favourable/unfavourable Glasgow Outcome Score or related score (Extended Outcome Score, modified Glasgow Outcome Scale) was the dichotomous outcome used for analysis (30 of 45 studies). For studies relating to infection prophylaxis and seizure prophylaxis, the outcomes utilised were pneumonia/mortality or seizure, respectively.

The summary characteristics of included trials are shown in [Table 1](#pone.0237879.t001){ref-type="table"}. Total sample size ranged from 24 patients to 10008 patients. The number of patients lost to follow-up ranged from 0 to 454 patients, however, four studies did not provide this measure. The breakdown of event counts for each trial group is shown in S2 Table in [S1 File](#pone.0237879.s001){ref-type="supplementary-material"}. Given these outcomes, Fisher's exact test was performed and the relative risk was also calculated. The corresponding *P* values are included in the table. The majority of study outcomes were "non-significant" (i.e. *P* ≥ 0.05) using either Fisher's exact test (30/43) or relative risk (24/43).

10.1371/journal.pone.0237879.t001

###### Characteristics of included trials.

![](pone.0237879.t001){#pone.0237879.t001g}

  Characteristic                          Median (IQR)   Min                 Max
  --------------------------------------- -------------- ------------------- -------
  Sample size                             87 (160)       25                  10008
   Number of events (intervention)        20 (19)        3                   1828
   Number of events (comparator)          19 (16)        4                   1728
  Lost to follow-up                       0 (9)          0                   454
  Fragility index (Fisher's exact test)   -3 (8)         -19                 79
   Positive                               3 (6)          1                   19
   Negative                               -6 (4.5)       -19                 -1
  Fragility index (relative risk)         -2 (9)         -14                 92
   Positive                               5 (6.5)        1                   92
   Negative                               -5 (2)         -14                 -1
  Endpoint *P* value                      **Fisher**     **Relative risk**   
   ≥0.05                                  30             24                  
   \<0.05--0.001                          4              4                   
   \<0.001                                9              15                  
  Performed sample size calculations      14 (yes)       29 (no)             

Fragility index analysis of the TBI management guidelines {#sec011}
---------------------------------------------------------

The fragility index (FI) based on Fisher's exact test or relative risk (one-tailed test) were evaluated for each trial, denoted FI~F~ and FI~RR~, respectively. For "significant" results, a positive FI was calculated; for "non-significant" results, a negative FI was obtained (see [Methods](#sec007){ref-type="sec"}). Although typically in the biomedical literature positive FI is calculated, the concept for negative FI is analogous \[[@pone.0237879.ref010]\], with the number of results needed to change the interpretation or conclusions of the study, and hence FI is presented here as a continuous result. The distribution of FI~F~ and FI~RR~ are shown in [Fig 1A](#pone.0237879.g001){ref-type="fig"}. Both distributions for FI~F~ and FI~RR~ were centred near zero, with a median of -3 (range -19 to 79) and -2 (-14 to 92), respectively. Most values also lay within a small range; 24/43 studies had an FI~F~ value between -5 and 5, while 28/43 had an FI~RR~ value between -5 and 5. We observed FI~RR~ to be greater or equal to FI~F~ ([Fig 1B](#pone.0237879.g001){ref-type="fig"}), consistent with the notion that Fisher's exact test is a conservative test \[[@pone.0237879.ref020]\]. That is, a greater disparity between event counts needed to be reached for Fisher's exact test to yield a "significant" result. Considering only positive FI values, the median FI~F~ and FI~RR~ were 3 (range 1 to 79, 14/43 studies) and 5 (range 1 to 92, 19/43 studies), while considering only negative FI values, the median FI~F~ and FI~RR~ were -6 (range -19 to -1, 29/43 studies) and -5 (range -14 to -1, 24/43 studies).

![Fragility index analysis of the TBI guidelines.\
(A) Histograms showing the distribution of FI~F~ (blue) and FI~RR~ (red). One outlier is not shown, corresponding to Study ID 23 (see S2 Table in [S1 File](#pone.0237879.s001){ref-type="supplementary-material"}) with FI~F~ and FI~RR~ equal to 79 and 92, respectively. (B) The relationship between FI~RR~ and FI~F~ is shown. The black line corresponds to equality. Most values for FI~RR~ lie above this line, indicating that FI~RR~ \> FI~F~ for these cases. (C) The relationship between FI (FI~F~, blue dot; FI~RR~, red cross) and sample size. The horizontal axis is scaled logarithmically. (D) The relationship between FI (FI~F~, blue dot; FI~RR~, red cross) and *P* value. The horizontal axis is scaled logarithmically. (E) Histogram showing the distribution of the number lost to follow-up. (F) Comparisons of the number lost to follow-up (LFU) and the magnitude of FI.](pone.0237879.g001){#pone.0237879.g001}

We did not observe a strong dependence of FI on sample size ([Fig 1C](#pone.0237879.g001){ref-type="fig"}). Two studies involving the same cohort of patients had sample sizes one to two orders magnitude greater than the remaining studies. Excluding these outliers (Study ID 23 and 24, in S2 Table in [S1 File](#pone.0237879.s001){ref-type="supplementary-material"}), the Pearson correlation coefficients between log~10~(sample size) and FI were -0.094 (95% CI: -0.39 to 0.22) and -0.020 (95%CI: -0.29 to 0.33), for FI~F~ and FI~RR~, respectively. On the other hand, FI was strongly inversely related to *P* value according to a linear-log relationship ([Fig 1D](#pone.0237879.g001){ref-type="fig"}). Excluding the same outliers, the Pearson correlation coefficients between log~10~(*P* value) and FI were -0.83 (95% CI: -0.91 to -0.71) and -0.92 (95% CI: -0.96 to -0.86), for FI~F~ and FI~RR~, respectively.

The number of patients lost to follow-up was also extracted, where that information was available (39/43 studies). This distribution is shown in [Fig 1E](#pone.0237879.g001){ref-type="fig"}. The number lost to follow-up was greater or equal to the magnitude of FI~F~ and FI~RR~ in 12/39 and 11/39 studies, respectively ([Fig 1F](#pone.0237879.g001){ref-type="fig"}, left); the number lost to follow-up was less than the magnitude of FI~F~ and FI~RR~ in 27/39 and 28/39 studies, respectively ([Fig 1F](#pone.0237879.g001){ref-type="fig"}, right). However, the magnitudes of FI~F~ and FI~RR~ were no more than 5 more than the number lost to follow-up in 31/43 studies. Thus, in most studies, the FI calculated using either Fisher's exact test or relative risk was a similar magnitude to the number lost to follow-up.

Analysis of fragility index {#sec012}
---------------------------

To better understand the relationship between FI, *P* value and sample size, we considered all possible combinations of binary outcomes for studies of different sizes. Studies of total size 80, 400, 2000, 10000 were included in the analysis. Each study was divided into two even groups, labelled intervention and comparator (i.e. control). For each study group, the number of events ranged from zero, up to the group size. For each combination of outcomes, Fisher's exact test was performed to determine if there was an association between outcome and study group. This statistical testing allowed contour maps to be generated, demonstrating the contours of different *P* value "levels" for various combinations of outcomes ([Fig 2A](#pone.0237879.g002){ref-type="fig"}). With Fisher's exact test known, FI~F~ could then be calculated for all combinations of outcomes and contour maps of FI~F~ could be generated in a similar manner ([Fig 2B](#pone.0237879.g002){ref-type="fig"}). In this section we considered positive values of FI~F~ only, although similar principles can be directly related to negative values of FI~F~. These contour plots demonstrate that for a fixed number of events in one study group, FI~F~ values vary linearly with the number of events in the other study group. This contrasts with the contours of *P* values, in that *P* values vary nonlinearly with event counts. Evidently, *P* values rapidly diminish when the disparity in event counts between the study groups widens.

![The relationship between FI, event counts and *P* values.\
(A) Contour plots of *P* values for Fisher's exact test. Three *P* value thresholds of 0.05, 0.001 and 1.0 x 10^−6^ were set as contour levels. (B) Corresponding contour plots for FI~F~. (C) The relation between FI~F~ and the number of events in the comparator group, for a fixed relative risk. Curves corresponding to a relative risk of 1.1, 1.2, 1.5 and 2.0 are shown. (D) Scatter plots showing the relationship between *P* value and FI~F~, for *P* \> 10^−6^. Hypothetical studies are balanced, with total size 80, 400, 2000 and 10000.](pone.0237879.g002){#pone.0237879.g002}

We also explored how FI~F~ varies with relative risk (RR) ([Fig 2C](#pone.0237879.g002){ref-type="fig"}). We considered combinations of event counts that produced the same RR, for four different values of RR; 1.1, 1.2, 1.5 and 2.0. These plots demonstrate that increasing the number of events in the comparator group results in a supra-linear increase in FI~F~, for positive values of FI~F~. For values of RR \< 1.0, it can similarly be shown that increasing the number of events in the comparator group results in a sub-linear increase in FI~F~, for positive values of FI. Further, for a given number of events in the comparator group, higher values of RR result in a greater FI~F~. Furthermore, the relationship between FI~F~ and *P* values is nonlinear and a given FI~F~ may be associated with a range of *P* values spanning multiple orders of magnitude ([Fig 2D](#pone.0237879.g002){ref-type="fig"}). Taken together, this analysis demonstrates the complex relationships between FI~F~ and sample size, event counts, relative risk and *P* values.

Power, sample size and fragility index {#sec013}
--------------------------------------

Given that FI is related to sample size and significance testing of study outcomes, we then explored if expected FI can be estimated *a priori*, in a similar manner to how power and sample size calculations are performed as part of study design. Notably, only 14/43 studies reported sample size calculations ([Table 1](#pone.0237879.t001){ref-type="table"}). We considered combinations of a range of study power, baseline risk and relative risk, and generated simulated studies in which the event counts were consistent with the alternative hypothesis (see [Methods](#sec007){ref-type="sec"} for further details). FI~F~ was then calculated based on these event counts and sample sizes.

The results of the simulations are shown in [Fig 3](#pone.0237879.g003){ref-type="fig"}. We observed that low powered studies are associated with a lower FI ([Fig 3A](#pone.0237879.g003){ref-type="fig"}). For studies with power 0.5, the median FI~F~ was -3 (range -12 to -2); for studies with power 0.6, the median FI~F~ was -2 (range -4 to -1); for studies with power 0.7, the median FI~F~ was 1 (range -2 to 9); for studies with power 0.8, the median FI~F~ was 4 (range 1 to 25); for studies with power 0.9, the median FI~F~ was 10 (range 2 to 55). Thus, only some, but not all, higher powered studies were associated with high values for FI~F~. The range of FI~F~ also widened with group size, as expected ([Fig 3B](#pone.0237879.g003){ref-type="fig"}), but not proportionately. The maximum FI~F~ observed was 55 for a study of total size 34078, with 1704 and 1874 events in the comparator and intervention arms, respectively. The corresponding simulation parameters were study power of 0.9, a baseline risk of 0.05 and a relative risk of 1.10. We also observed that FI~F~ was only weakly related to baseline risk ([Fig 3C](#pone.0237879.g003){ref-type="fig"}). In contrast, higher values of FI~F~ were realized with relative risk values approaching 1.0, and the demarcation between different power levels was evident ([Fig 3D](#pone.0237879.g003){ref-type="fig"}). This is partly explained by the greater sample sizes required to detect a significant relative risk, particularly for higher power levels. Taking all positive FI~F~ values together, we found the median to be 5 (range 1 to 55; 437 values).

![Sample size calculations and FI in simulated studies.\
(A) Scatterplot showing the relationship between FI and study power (1---β). (B) Scatterplot showing the relationship between FI and group size (half the total study size). The group size is shown on a logarithmic axis. (C) Scatterplot showing the relationship between FI and the baseline event rate in the comparator group. (D) Scatterplot showing the relationship between FI and relative risk. Colours represent power levels as in Panel (A).](pone.0237879.g003){#pone.0237879.g003}

Discussion {#sec014}
==========

Fragility index analysis of the TBI literature and comparison with other studies {#sec015}
--------------------------------------------------------------------------------

Fragility index analysis of the BTF guidelines for the management of severe TBI (4^th^ edition) \[[@pone.0237879.ref017]\] revealed that most studies were associated with a low FI. The trends seen with FI~RR~ were similar to those seen with FI~F~, although FI~RR~ was typically greater than FI~F~. This is consistent with the notion that Fisher's exact test is a conservative test for association \[[@pone.0237879.ref020]\]. Nevertheless, we observed no other advantage in utilising relative risk for FI calculations. We demonstrated that 24/43 studies had an FI~F~ value between -5 and 5, while 28/43 had an FI~RR~ value between -5 and 5. Furthermore, the magnitudes of FI~F~ and FI~RR~ was no more than 5 more than the number lost to follow-up in 32/43 studies. We also showed that FI was not strongly related to sample size, suggesting that some of the larger studies hinged on proportionately fewer events. Collectively, these findings suggest that the evidence base supporting the severe TBI management guidelines may be considered "fragile", in that the interpretation of study findings can be swayed by a small number of events. The median positive FI~F~ was 3, which is similar to other studies that have evaluated FI in different fields \[[@pone.0237879.ref006]--[@pone.0237879.ref009], [@pone.0237879.ref011]\]. Thus our findings are not unique to the severe TBI management guidelines, but appear consistent with the view that much of the biomedical literature is founded on weak evidence \[[@pone.0237879.ref021]\]. The fragility indices obtained from the BTF guidelines are not being used in this paper to examine the quality of the underlying papers or their clinical implications. Rather, the results are useful in forming a critique of FI itself. We do not advocate for any of these papers or the BTF guidelines themselves to be downgraded in their validity. The challenges of performing RCTs in this population have been well described comprising a heterogenous population with an incompletely understood disease, requiring precise titration of individual therapies. For this reason, RCTs in TBI are often small, expensive and inherently "fragile" \[[@pone.0237879.ref016]\]. Future research in this field should emphasise sound methodology, large enrolment, patient centred outcomes, and place less weight on *P* values to determine clinical significance. Reporting results with confidence intervals would also provide greater context and relevance upon which to make clinical decisions. Rather than drawing firm conclusions about the severe TBI management guidelines, we discuss below the weaknesses associated with FI.

Implications on the interpretation and utility of fragility index {#sec016}
-----------------------------------------------------------------

Like other areas of clinical research, recruiting participants for TBI management studies can be challenging, and may involve multiple centres in multiple countries over many years. Accordingly, prospective randomised studies typically perform sample size calculations prior to recruitment. These calculations necessarily make assumptions about the expected effect size and population variance, and seek to strike a balance between ensuring the study is sufficiently powered to detect a statistically significant result and over-recruitment of patients \[[@pone.0237879.ref022]\]. To determine how these considerations may affect FI, we performed sample size calculations for a range of desired power levels, baseline risk and relative risk. The range of FI values realised was small, up to several orders of magnitude smaller than the study size ([Fig 3](#pone.0237879.g003){ref-type="fig"}). Expectedly, underpowered combinations were associated with smaller FI values. It is well known that many RCTs in the biomedical literature are underpowered \[[@pone.0237879.ref023], [@pone.0237879.ref024]\]. It could therefore be said that by design, many studies are inadvertently "fragile". In this light, evaluation of FI may be akin to *post hoc* power analysis, itself an uninformative exercise \[[@pone.0237879.ref025]\]. Surprisingly however, the median of all the positive FI values in these simulations was 5, and even moderately large, well-powered studies can produce "low" values of FI (\< 20). Thus, low values of FI are ambiguous. Furthermore, the highest values of FI were only seen in the largest and highest-powered studies To demonstrate this point, the notable outlier in our fragility calculations was the CRASH trial \[[@pone.0237879.ref026]\] with a FI~F~ and FI~RR~ of 79 and 92, respectively. With 10,008 participants, it was over ten times larger than the next largest trial \[[@pone.0237879.ref027]\] with 957 enrolments, and was powered to detect a 2% absolute reduction in mortality \[[@pone.0237879.ref028]\]. Taken together, these examples highlight key pitfalls with reliance on FI as a measure of robustness.

On face value, FI offers a straightforward interpretation of the susceptibility of a trial to change in the number of events, and this has led to a large number of studies applying FI analysis to various topics in recent years \[[@pone.0237879.ref002]--[@pone.0237879.ref011], [@pone.0237879.ref024]\]. However, such an interpretation overlooks other shortcomings associated with FI. To explore these, we extended our analysis of fragility index with numerical simulations ([Fig 2](#pone.0237879.g002){ref-type="fig"}). Our approach is different to that taken by Carter et al. \[[@pone.0237879.ref012]\] in that we exhaustively considered all possible combinations of event counts for balanced studies of dichotomous outcomes. Although many combinations of event counts may never be realised in clinical trials, this approach enables a complete appreciation of the probability landscape to be obtained. The contour maps demonstrate the essential feature that FI~F~ varies linearly with event counts. For "significant" results where Events(Intervention) \> Events(Comparator), corresponding to the top left regions of panels in [Fig 2B](#pone.0237879.g002){ref-type="fig"}, FI~F~ is simply the horizontal distance to the boundary of significance. Similarly, for "significant" results where Events(Intervention) \< Events(Comparator), corresponding to the bottom right regions in [Fig 2B](#pone.0237879.g002){ref-type="fig"}, FI~F~ is the vertical distance to the boundary of significance. These two scenarios are depicted schematically in [Fig 4](#pone.0237879.g004){ref-type="fig"}. Since FI is based solely on the boundary of significance, the linear association of FI with event counts will remain regardless of statistical methodology or outcome measure. In contrast, *P* values vary non-linearly ([Fig 2A](#pone.0237879.g002){ref-type="fig"}) and consequently, the relation between FI~F~ and *P* values is highly non-linear ([Fig 2D](#pone.0237879.g002){ref-type="fig"}). Although the two values are inversely correlated \[[@pone.0237879.ref012]\], a wide range of FI~F~ values may be realised for a given *P* value and vice versa. Thus, FI~F~ fails to accurately represent the probability landscape for rejecting the null hypothesis in the null hypothesis significance testing (NHST) framework and does not bear a robust relationship to the strength of the evidence.

![Schematic description of FI.\
(A) In the scenario where Events(Intervention) \> Events(Comparator), FI is the horizontal distance to the boundary curve corresponding to *P* = 0.05 (dashed line). (B) In the scenario where Events(Comparator) \> Events(Intervention), FI is the vertical distance to the boundary curve corresponding to *P* = 0.05 (dashed line).](pone.0237879.g004){#pone.0237879.g004}

In isolation, *P* values carry little meaning and are of limited clinical utility. Rather, a *P* value should be reported with an effect size and confidence interval. This notion has previously been detailed in the ASA's statement on *P* values \[[@pone.0237879.ref029]\] and extensively elsewhere in the scientific literature. In a similar vein, in [Fig 2C](#pone.0237879.g002){ref-type="fig"} we show how FI varies with relative risk and event counts. For a given relative risk, smaller event counts in the comparator (or control) group are associated with a smaller FI. Specifically, these results demonstrate that FI is modified by effect size and reinforce the notion that FI should not be considered in isolation. However, the complex relationship between FI and sample size, baseline and relative risks, and *P* value hinders the ability to draw comparisons across different studies.

The dichotomization of *P* values inherent to the calculation of FI epitomises the conventional (albeit arbitrary) selection of the *P* = 0.05 threshold for "statistical significance" in the NHST framework. According to this threshold, a *P* value of 0.049 is considered "significant" while a *P* value of 0.051 is considered "non-significant", despite a nearly indistinguishable Type I error rate. Such *P* values should instead be regarded as providing similarly "weak" evidence for the null hypothesis. Importantly, the dichotomization of *P* values and emphasis on "statistical significance" has demonstrable effects on the reporting of results in the biomedical literature. Many studies have shown not only a positive skew in the distribution of reported *P* values but also a large step-change in the *P* value distribution at 0.05 \[[@pone.0237879.ref030]--[@pone.0237879.ref033]\]. Such presence of systematic bias in the literature is likely to have far-reaching consequences\[[@pone.0237879.ref021]\]. Thus, it is our view that FI places undue importance on statistical significance in the interpretation and application of study results.

Limitations of the study {#sec017}
------------------------

This study had a number of limitations. The fragility index analysis was restricted only to RCTs from Part 1 (treatment) of the BTF TBI management guidelines and did not encompass the broader TBI literature \[[@pone.0237879.ref016]\]. No studies from Parts 2 (monitoring) or 3 (threshold) were included. It is also possible that many less significant (or negative) results were not collated into these guidelines. Furthermore, only one outcome per study was considered, typically the primary outcome. Since secondary outcomes are often less powered \[[@pone.0237879.ref034]\], this may inflate the FI values. The TBI management guidelines also comprise a heterogeneous collection of literature, encompassing medical and surgical, as well as diagnostic and monitoring interventions. Thus, individual studies may not be directly comparable across topics. Finally, our numerical simulations did not take into account the "natural" distribution of parameter ranges found in the literature. Therefore, the distribution of the simulated FI values may not accurately reflect the "true" distribution in the literature.

Notwithstanding these limitations, the FI values obtained in both the analysis of TBI guidelines and the numerical simulations were closely matched to those reported in previous studies \[[@pone.0237879.ref006]--[@pone.0237879.ref009], [@pone.0237879.ref011]\]. This suggests that the range of FI may be relatively insensitive to many of these factors.

Conclusions {#sec018}
===========

This study is not an indictment on the evidence underlying the published guidelines for management of severe TBI. Rather, we caution the over-zealous use of fragility index as an indicator of robustness. Power and sample size simulations suggests that many studies are expected to be associated with a small FI *a priori*. Furthermore, the metric over-simplifies the complex, non-linear relationships between sample size, *P* value and effect size and in isolation has limited utility. In combination, it is unclear how much additional information FI provides since it cannot be meaningfully compared across different studies. Neither should FI be taken as a proxy or substitute for *P* value as these are not equivalent. That FI places undue importance on the "significance" of *P* values is in itself hazardous, and perpetuates the fallacy that results are real or not based on an arbitrarily chosen threshold.
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4\. What are, in the view of the authors, the clinical implications of the FIs in TBI trials? Should recommendations in guidelines be downgraded based on fragile studies? I completely concur with the authors\'assessment of the biomedical literature\'s over-reliance on statistical significance. I personally am in favor of reporting confidence intervals.

5\. The authors mention the Fisher test to be a conservative measure of association. They do not mention other methodologies which are used in recent years ( e.g.proportional odds analysis in recent stroke trials or in RESCUE ICP), would this be a solution for more robust conclusions?

6\. The CRASH trial is an outlier with a high FI, do the authors consider it a model for future research? Please expand in the discussion

7\. Given the difficulties of including patients in TBI RCTs, the heterogeneity of the disease phenotype, the high costs associated with small fragile trials, what would be the solution for the future of TBI evidence generation in the authors\'opinion? Please expand in the discussion.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Victor Volovici

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237879.r002

Author response to Decision Letter 0

3 Aug 2020

We thank Reviewer \#1 for useful comments. Our responses are detailed below.

Reviewer \#1: The authors present an elegant and well-written account of the fragility index in TBI evidence included in the BTF Guidelines. The paper is valuable, the simulations are relevant and deserve publication. I do have, however, some comments that need to be addressed:

1\. The fragility index was, in essence, meant to be applied to \"statistically significant\" findings. Spin-offs such as the \"reverse FI\" have been used for non-inferiority trials. The authors chose to apply the FI to non-significant findings and to report the \"negative FI\". I would like to ask the authors to motivate their choice methodologically: A non-significant trial with an FI of -2 would have been a significant trial with an FI of 1 had more patients been included who would have had a specific event. Is this something clinically relevant? How should we interpret the \"fragility\" of non-significant trials? The idea of the FI is that we base clinical practice and policy on trials with low FI, which makes the evidence base on which we so heavily rely on \"shaky\". Should a fragile non-significant trial influence policy in the view of the authors? In any case, I would like to see the two types of FI reported separately, both in the table and in the text, \"FI\" and \"negative FI\" and I think a discussion of this choice and of the meaning of fragile non-significant trials and their impact should be done.

Our work is focused on the limitations of fragility index and we conclude that fragility index is not a meaningful indicator of robustness. Therefore, we respectfully contend that labelling a significant/non-significant trial as "fragile" is not particularly revealing.

In the spirit of fragility index, being the number of events that need to change to alter the interpretation of a study outcomes, we included negative FI to demonstrate that both positive FI and negative FI are not meaningful measures. We have made this more explicit in the Results section "Fragility index analysis of the TBI management guidelines" and cited Shen et al (2019, Neurosurg Rev) as a paper that presents negative FI.

As per the Reviewer's useful suggestion, we have separated positive and negative FI in the Results section "Fragility index analysis of the TBI management guidelines" and in Table 1. For much of our work, we amalgamated the negative and positive FI in Fig 1 to demonstrate the "continuous" nature of FI. It simply reflects the distance to the threshold of significance (Fig 4). Specifically, most FI values from the TBI studies (both positive and negative) were small in magnitude and fall between -5 and 5 (as we elaborate in the Results). Again, in our simulations, we demonstrate that many study designs will yield a small negative/positive FI (Fig 3). Therefore, we respectfully also argue that separating positive and negative FI does not alter the interpretation that FI is not a useful measure of robustness. The Results section "Analysis of fragility index" concerns only positive FI.

2\. The authors do not cite Bragge et al 2016 J Neurotrauma and did not choose to base their calculations on the excellent overview of RCTs in Trauma presented in the respective State-of-Science paper. Can the authors motivate this decision?

We have now cited this publication, including in the Discussion section "Limitations of the study". As per our original submission, we elected to use the Brain Trauma Foundation guidelines for management of severe TBI as our source of RCTs. Arguably, fragility index calculations could also have been performed on RCTs presented in Bragge et al (2016). However, this does not alter our interpretation of fragility index, as demonstrated by the simulations, or how we apply this interpretation to the TBI literature.

3\. What conclusions do the authors draw about the set-up of future trials based on their simulations? Can they summarize the advice regarding future trial methodology in the discussion?

The simulations were focused on the properties and pitfalls of fragility index, and demonstrating its limited use in the interpretation of trial results. The simulations were therefore not designed to evaluate study design in general. Although considerations for future trial methodology in TBI research is very important, this is beyond the scope of our work.

4\. What are, in the view of the authors, the clinical implications of the FIs in TBI trials? Should recommendations in guidelines be downgraded based on fragile studies? I completely concur with the authors\"assessment of the biomedical literature\"s over-reliance on statistical significance. I personally am in favor of reporting confidence intervals.

Due to the limitations associated with the use of FI, we do not think it is appropriate to draw conclusions about the robustness of TBI trials or alter/downgrade the recommendations in the guidelines. We have made this more explicit in the Discussion section "Fragility index analysis of the TBI literature and comparison with other studies".

5\. The authors mention the Fisher test to be a conservative measure of association. They do not mention other methodologies which are used in recent years ( e.g.proportional odds analysis in recent stroke trials or in RESCUE ICP), would this be a solution for more robust conclusions?

We argue that fragility index itself is not a useful measure of robustness. The choice of statistical methodology/outcome measure does not qualitatively influence fragility index (Figure 4) or overcome its limitations. For example, we have demonstrated this with our calculations of fragility index based on relative risk. While other methodologies (e.g. proportional odds analysis) may yield quantitatively different thresholds for "significance", any statistical test does not change the notion that fragility index is simply the "horizontal distance" to the threshold (Figure 4). We have elaborated on this in the Discussion section "Implications on the interpretation and utility of fragility index".

6\. The CRASH trial is an outlier with a high FI, do the authors consider it a model for future research? Please expand in the discussion

We have elaborated on the CRASH trial in the Discussion section "Implications on the interpretation and utility of fragility index". The trial is indeed a notable outlier and over ten times larger than the next largest study included in our analysis. However, as our work is focused on the pitfalls of fragility index, we limit our discussion by mentioning "the highest values of FI were only seen in the largest and highest-powered studies". We are hesitant to suggest that the CRASH trial should be used as a model for future research (even though it may well be), as there are many other considerations beyond the scope of fragility index analysis that contribute to the quality of research.

7\. Given the difficulties of including patients in TBI RCTs, the heterogeneity of the disease phenotype, the high costs associated with small fragile trials, what would be the solution for the future of TBI evidence generation in the authors\"opinion? Please expand in the discussion.

Our work is on the limitations of using fragility index. Our simulations demonstrated even large, well-powered studies can be associated with a "low" fragility index. Our results, taken together, indicate that fragility index is not a useful measure robustness. Thus, we are unable to use it to meaningfully critique the TBI literature. Therefore, evidence generation in TBI research, or indeed other fields of (biomedical) research, should not be altered on the basis of fragility index analyses alone. On account of this, we respectfully argue that offering an opinion on evidence generation is not relevant to our work.
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If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Dear Dr. To:
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